Anticoagulant effects of inhaled unfractionated heparin in the dog as determined by partial thromboplastin time and factor Xa activity
- 20 July 2015
- journal article
- clinical trial
- Published by Wiley in Journal of Veterinary Emergency and Critical Care
- Vol. 26 (1) , 132-136
Abstract
To evaluate the anticoagulant effects of inhaled heparin in dogs. This study was conducted in 3 phases. In phase 1, bronchoalveolar lavage fluid (BALf) was collected to generate an in vitro calibration curve to relate heparin concentration to the activated partial thromboplastin time (aPTT). In phase 2, heparin was administered via nebulization to determine the threshold dose needed to prolong systemic aPTT. In phase 3, the local anticoagulant activity of inhaled heparin was determined by measurement of BALf anti-Xa activity and aPTT. University teaching hospital. Six healthy intact female Walker Hounds were used in this study. Two dogs were used for each phase. Inhaled unfractionated sodium heparin was administered in doses ranging from 50,000 to 200,000 IU. In vitro addition of heparin to BALf caused a prolongation in aPTT. Inhaled heparin at doses as high as 200,000 IU failed to prolong systemic aPTT, and a threshold dose could not be determined. No significant local anticoagulant effects were detected. Even at doses higher than those known to be effective in people, inhaled heparin appears to have no detectable local or systemic anticoagulant effects in dogs with the current delivery method.Keywords
Funding Information
- Mississippi State University College of Veterinary Medicine Office of Research and Graduate Studies Internal Grant Program
This publication has 11 references indexed in Scilit:
- Inhalable Liposomes of Low Molecular Weight Heparin for the Treatment of Venous ThromboembolismJournal of Pharmaceutical Sciences, 2010
- Safety and Tolerability of Inhaled Heparin in Idiopathic Pulmonary FibrosisJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- A phase 1 trial of nebulised heparin in acute lung injuryCritical Care, 2008
- Inhaled heparin in cystic fibrosisEuropean Respiratory Journal, 2006
- Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogsVeterinary Clinical Pathology, 2005
- Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary routeProceedings of the National Academy of Sciences, 2004
- The Impact of Heparin Compounds on Cellular Inflammatory Responses: A Construct for Future Investigation and Pharmaceutical DevelopmentJournal of Thrombosis and Thrombolysis, 2003
- Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogsAmerican Journal of Veterinary Research, 2001
- Heparin Inhibits Eicosanoid Metabolism and Hyperventilation-induced Bronchoconstriction in DogsAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Inhaled heparin is effective in exacerbations of asthmaRespiratory Medicine, 2000